Logo image of LFST

LIFESTANCE HEALTH GROUP INC (LFST) Stock Fundamental Analysis

NASDAQ:LFST - Nasdaq - US53228F1012 - Common Stock - Currency: USD

5.42  -0.18 (-3.21%)

After market: 5.39 -0.03 (-0.55%)

Fundamental Rating

3

Overall LFST gets a fundamental rating of 3 out of 10. We evaluated LFST against 102 industry peers in the Health Care Providers & Services industry. LFST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LFST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LFST had negative earnings in the past year.
In the past year LFST had a positive cash flow from operations.
In the past 5 years LFST always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: LFST reported negative operating cash flow in multiple years.
LFST Yearly Net Income VS EBIT VS OCF VS FCFLFST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

LFST has a Return On Assets (-1.68%) which is comparable to the rest of the industry.
LFST has a Return On Equity of -2.43%. This is comparable to the rest of the industry: LFST outperforms 50.98% of its industry peers.
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROIC N/A
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
LFST Yearly ROA, ROE, ROICLFST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

LFST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFST Yearly Profit, Operating, Gross MarginsLFST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

4

2. Health

2.1 Basic Checks

LFST does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFST has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LFST has more shares outstanding
Compared to 1 year ago, LFST has a worse debt to assets ratio.
LFST Yearly Shares OutstandingLFST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
LFST Yearly Total Debt VS Total AssetsLFST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 2.12 indicates that LFST is not a great score, but indicates only limited risk for bankruptcy at the moment.
LFST has a Altman-Z score of 2.12. This is comparable to the rest of the industry: LFST outperforms 48.04% of its industry peers.
LFST has a debt to FCF ratio of 2.80. This is a good value and a sign of high solvency as LFST would need 2.80 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.80, LFST is doing good in the industry, outperforming 79.41% of the companies in the same industry.
LFST has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.19, LFST is in the better half of the industry, outperforming 69.61% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Altman-Z 2.12
ROIC/WACCN/A
WACC8.8%
LFST Yearly LT Debt VS Equity VS FCFLFST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
LFST has a Current ratio (1.47) which is in line with its industry peers.
A Quick Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.47, LFST perfoms like the industry average, outperforming 55.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
LFST Yearly Current Assets VS Current LiabilitesLFST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

LFST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.17%, which is quite impressive.
The Revenue has grown by 16.31% in the past year. This is quite good.
Measured over the past years, LFST shows a very strong growth in Revenue. The Revenue has been growing by 42.55% on average per year.
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%

3.2 Future

Based on estimates for the next years, LFST will show a very strong growth in Earnings Per Share. The EPS will grow by 40.71% on average per year.
The Revenue is expected to grow by 12.39% on average over the next years. This is quite good.
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LFST Yearly Revenue VS EstimatesLFST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
LFST Yearly EPS VS EstimatesLFST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LFST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFST Price Earnings VS Forward Price EarningsLFST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

LFST's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. LFST is more expensive than 60.78% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, LFST is valued a bit cheaper than the industry average as 63.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.7
EV/EBITDA 50.7
LFST Per share dataLFST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as LFST's earnings are expected to grow with 40.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.97%
EPS Next 3Y40.71%

More info and screens

0

5. Dividend

5.1 Amount

LFST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFESTANCE HEALTH GROUP INC

NASDAQ:LFST (6/12/2025, 5:20:02 PM)

After market: 5.39 -0.03 (-0.55%)

5.42

-0.18 (-3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners35.32%
Inst Owner Change2.27%
Ins Owners6.62%
Ins Owner Change1.75%
Market Cap2.11B
Analysts81.33
Price Target8.89 (64.02%)
Short Float %7.17%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.99%
Min EPS beat(2)43.98%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)10.6%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)9.87%
EPS beat(12)8
Avg EPS beat(12)7.21%
EPS beat(16)8
Avg EPS beat(16)-4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.11%
Min Revenue beat(2)-1.94%
Max Revenue beat(2)1.72%
Revenue beat(4)2
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-1.94%
Max Revenue beat(4)1.72%
Revenue beat(8)4
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)0.23%
Revenue beat(16)8
Avg Revenue beat(16)0.04%
PT rev (1m)-1.35%
PT rev (3m)-3.17%
EPS NQ rev (1m)11.76%
EPS NQ rev (3m)-50%
EPS NY rev (1m)11.62%
EPS NY rev (3m)32.36%
Revenue NQ rev (1m)-2.1%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.64
P/FCF 20.7
P/OCF 16.74
P/B 1.45
P/tB N/A
EV/EBITDA 50.7
EPS(TTM)-0.1
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.26
FCFY4.83%
OCF(TTM)0.32
OCFY5.97%
SpS3.3
BVpS3.75
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7.93%
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Debt/EBITDA 5.68
Cap/Depr 38.82%
Cap/Sales 1.88%
Interest Coverage N/A
Cash Conversion 259.18%
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z 2.12
F-Score7
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)65.59%
Cap/Depr(5y)98.78%
Cap/Sales(3y)4.95%
Cap/Sales(5y)7.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%
EBIT growth 1Y92.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year429.54%
EBIT Next 3Y96.96%
EBIT Next 5YN/A
FCF growth 1Y682.28%
FCF growth 3YN/A
FCF growth 5Y98.76%
OCF growth 1Y202.74%
OCF growth 3Y124.79%
OCF growth 5Y44.39%